Neurologic Disorders

OTL-200 is an ex vivo autologous hematopoietic stem cell gene therapy.

Temozolomide is the second drug to receive a labeling update under Project Renewal.

A regulatory decision is expected by October 8,2023.

The new sprinkle formulation is intended to be opened for sprinkling on soft foods prior to administration.

Individual patient data meta-analysis shows increased risk for dementia for those with untreated hypertension.

Among patients with ADRD receiving care from a home health agency, antipsychotic use was tied to less improvement in activities of daily living.

Significant reductions were seen in dementia risk for rivaroxaban, apixaban, and dabigatran versus warfarin in network meta-analysis

Ravulizumab is a long-acting C5 complement inhibitor.

Lower treatment retention rates seen with 30-day, out-of-pocket costs $150 or greater.

Significant benefit seen as early as 8 days compared with placebo.

The phase 3 study evaluated pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy who are taking background corticosteroids.

Valbenazine 40mg achieved greater placebo-adjusted improvement in chorea as early as week 2 and sustained greater efficacy through week 12 compared with placebo.

Tyruko is an integrin receptor antagonist.

TSHA-102 is an investigational adeno-associated virus 9 gene transfer therapy.

Findings seen for tetanus and diphtheria, shingles, and pneumococcus vaccines.

Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period.

Few older adults with MCI or mild dementia were eligible for lecanemab, aducanumab after applying clinical trial criteria.

No significant difference seen for death or cerebral palsy at 2 years’ corrected age for those receiving magnesium, placebo.